Terms: = Liver cancer AND PTPN13, PTP1E, 5783, ENSG00000163629, PTPLE, PTPL1, PNP1, PTP-BAS, DKFZp686J1497, Q12923, FAP-1, PTP-BL AND Prognosis
3 results:
1. Anti-oncogene ptpn13 inactivation by hepatitis B virus X protein counteracts IGF2BP1 to promote hepatocellular carcinoma progression.
Yan Y; Huang P; Mao K; He C; Xu Q; Zhang M; Liu H; Zhou Z; Zhou Q; Zhou Q; Ou B; Liu Q; Lin J; Chen R; Wang J; Zhang J; Xiao Z
Oncogene; 2021 Jan; 40(1):28-45. PubMed ID: 33051595
[TBL] [Abstract] [Full Text] [Related]
2. Tumour-suppressive role of ptpn13 in hepatocellular carcinoma and its clinical significance.
Zhan H; Jiang J; Luo C; Sun Q; Ke A; Sun C; Hu J; Hu Z; Hu B; Zhu K; Fan J; Zhou J; Huang X
Tumour Biol; 2016 Jul; 37(7):9691-8. PubMed ID: 26801674
[TBL] [Abstract] [Full Text] [Related]
3. Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial.
Boige V; Raoul JL; Pignon JP; Bouché O; Blanc JF; Dahan L; Jouve JL; Dupouy N; Ducreux M;
Br J Cancer; 2007 Oct; 97(7):862-7. PubMed ID: 17876335
[TBL] [Abstract] [Full Text] [Related]
